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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not use of
electroanalgesic therapy decreases neuropathic pain symptoms in diabetic patients
STUDY DESIGN: Review of a 2 randomized control trial published in 2013 and 2011 published in the
English language and an observational study published in 2010 in the German language translated into
English.
DATA SOURCES: One randomized, double-blind control trial comparing frequency-modulated
electromagnetic stimulation vs placebo in reduction of diabetic neuropathic pain, one randomized, control
trial comparing microcurrent transcutaneous electric nerve stimulation vs placebo in reduction of painful
diabetic neuropathy and a observational study using baseline comparison of the observed group at the
beginning of the treatment vs the end of the treatment.
OUTCOMES MEASURED: Pain is measured through various scales administered in their respective
studies. The Visual Analogue Scale was used to measure day and night pain, the Neuropathic Pain Score
administered to assess pain intensity and the Thermal Sensory Analyzer to assess cold, warmth, cold pain
and heat pain.
RESULTS: Bosi et al. demonstrated significant reduction in day and night pain in treatment group vs
placebo group. Gossrau et al. did not conclude that applied transcutaneous electrotherapy showed superior
reduction of pain compared to placebo group. Moharic and Burger concluded there were no statistically
significant changes or thermal pain perception thresholds after transcutaneous electrotherapy.
CONCLUSIONS: Although some pain relief was reported by participants in these studies,

collectively, all three studies have were unable to exhibit significant evidence of lasting DPN
pain relief using electroanalgesic treatment.
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INTRODUCTION
Peripheral neuropathy is a common complication in diabetes type 1 and type 2 patients
that often manifests as pain, paresthesia, and numbness in their upper and lower extremities.1,2
The pathology of diabetic peripheral neuropathy (DPN) is complex and primarily involves
atherosclerosis of the endoneural vascular supply leading to nerve ischemia and axonal
atrophy.2,3 Diabetic peripheral neuropathy (DPN) typically presents as a loss of sensation
beginning in the toes and progresses proximally. Patients often describe chronic neuropathic pain
as burning, pins and needle tingling, and diffuse aching.1 Hyperalgesia, allodynia and loss of
balance and coordination are also complaints associated with DPN.6 Manifestations of
symptoms range from mild to severe and in some cases physical debilitation.6
25.8 million people in the United States have diabetes and 79 million people are
prediabetic. It is estimated that 60-70% of diabetes patients suffer some form of neuropathy. 27%
of direct medical cost of diabetes is attributed to diabetic peripheral neuropathy totaling a cost of
$10.9 billion dollars spent annually on treatment.5 Although the mechanism of the disease is
poorly understood, it is widely thought that hyperglycemia causing changes in the blood vessels
supplying the peripheral nerves underlie the mechanisms involved in microvascular damage and
hypoxia.7
Management of painful DPN poses a large challenge to the medical community.3 Current
treatment only reduce associated symptoms by 30-50% and due to lack of sufficient knowledge
concerning the pathogenesis of the disease there are no curative treatments that can fully provide
complete relief of symptoms.7 There are five main classes of medications used for the
management of peripheral neuropathic pain: tricyclic antidepressants, anticonvulsants, serotonin-
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norepinephrine reuptake inhibitors, opiates and topical analgesics.7 Medications are the mainstay
of DPN treatment but they are unsuccessful in providing larger numbers of relief
notwithstanding the long list of adverse effects and complex drug interactions for patients on
medications for comorbid conditions.7
Based on the gate control theory electroanalgesic therapy is being explored in providing a
physiological block and activating an pain inhibitory system as a means to address the
neuropathic pain in diabetic patients.
OBJECTIVE
The objective of this systematic review is to determine whether or not electroanalgesic
therapy decreased neuropathic pain in diabetic patients.
METHODS
The populations chosen were diabetic patients > 18 years old who suffer from peripheral
neuropathic pain with the studies further selecting subjects with symptomatic DPN affecting the
lower extremities that have suffered symptoms more than a year. The intervention in all studies
were electroanalgesic therapy via micro-transcutaneous electrical nerve stimulation (TENS) units
or frequency modulated neural stimulation (FREMS) units.1
Key words used in the searches were “diabetic neuropathies”, “transcutaneous nerve
stimulation”, and “electroanalgesia”. All articles were published in peer-reviewed journals and
in the English language with one article translated into English from the German language. The
author searched the articles through PubMed and selected articles based on the relevance to the
clinical question, human subjects and the outcomes that included patient-oriented evidence that
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matters. Inclusion criteria consisted of studies where design was either observational or
randomized, single blinded or double blinded, placebo controlled, studies that included diagnosis
of diabetes mellitus type 1 or type 2 for at least 1 year, patients who experience symptomatology
of painful diabetic neuropathy, and patients > 18 years of age. In the study conducted by Bosi et
al, further selection of participants included patients with a HbA1c <11.0%, abnormalities in
amplitude, latency or conduction velocity in at least one motor nerve, and a Michigan Diabetes
Neuropathy Score (MDNS) equal or greater than 7 points.1 Exclusion criteria in this study
consisted of patients with previous treatment with TENS or other electrotherapy for DPN,
implantable pacemaker, defibrillator or neurostimulator, presence of active foot ulcer and/or
previous major amputation of lower extremities and any concomitant sever disease limiting
compliance to study procedures or life expectancy. The criteria for patients selected in the
Gossrau et al study included a HbA1c <8.0%, gammaglutamyltransferase (GGT) <1.4 µmol/L,
normal creatinine and blood cell counts; and current pain intensity of at least 4/10 on a numerical
rating scale (NRS).2 The exclusion criteria in this study consisted of patients with implanted
pacemakers, heart defibrillators, brain stimulators, history of alcohol abuse and malignancies.2
Selection of patients in the Moharic and Burger study was made at an outpatient clinic for
diabetic foot with diabetes mellitus type 2, further selecting patients who agreed to at least two
items of the Michigan Neuropathy Screening Instrument (MNSI).3 The exclusion criteria in the
Moharic and Burger study included patients with other non-diabetic neuropathies, significant
pain of other etiologies or peripheral vascular disease.
In the study conducted by Bosi et al treatment was administered via the Aptiva device.1
Four pairs of electrodes were applied to both lower extremities and biphasic sequences of
asymmetric and electrically balanced pulses with an active phase of high negative voltage spike
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(-300V) and short duration 10-100 microseconds proceeded by a recharging phase of low voltage
and long duration (.9-999ms) with variable pulse frequency 1-1000Hz were applied to treatment
groups.1 Electrodes were also applied to the placebo group but no electrical impulses were
administered. FREMS or placebo treatments were 30 minutes in length and completed sessions
consisted of 10 consecutive treatments administered at least 24 hours a part within a 21 day time
frame.1 Studies by Gossrau et al. were conducted over a 4 week period consisting of 3 visits per
week. The treatment group were administered 30 minutes of low-frequency microcurrent (30-40
microA) via skin electrodes placed on the proximal dorsum pedis and on top of caput fibulae on
both legs. In the placebo group the electrodes were not connected to the TENS unit-microcurrent
and did not induce sensations or muscle twitching.2 Duration of the study consisted of 3 visits
over a 4 week period. In the last study reviewed by Moharic and Burger titled, transcutaneous
electrotherapy was administered to patients by portable unit generating current with a pulse
width of 30-260ms, intensity 0-14mA and frequency 2-150 mHz in constant, burst or modulated
form. 5 x 5cm self-adhesive PALS electrodes placed proximally 10 cm above internal or
external malleolus and distally in the sole or dorsum of the foot, alternating the two
configurations each day on both lower extremities x 3 consecutive hours daily for 3 weeks.3
OUTCOMES MEASURED
Outcomes measured in these studies were all based on the reduction of pain scale rating
reported by patients. Other outcomes measured were cold, warm, cold pain and heat pain
thresholds, vibration perception thresholds and touch perception thresholds, pain intensity, pain
interference with activity of daily life and depression and tactile sensations. Indices utilized to
measure outcomes were: Thermal Sensory Analyser, Vibratory Sensory Analyser, Von Frey’s
hair, Pain Disability Index, Neuropathic Pain Score, Center for Epidemiologic Studies
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Table 1: Demographics and characteristics of included studies
Study

Type

#Pts

Inclusion Criteria

Exclusion Criteria

41

Age
years
67+ 12

Gossrau1

RCT

Bossi2

Moharic3

W
D
0

Interventions

diagnosis of type 1 or
type 2 diabetes mellitus
for at least 1 year and
have painful diabetic
neuropathy (PND),
diagnosed by an
experienced neurologist
or diabetologist, HbA1c
<8%, GGT < 1.4µmols/L,
normal results for
creatinine and blood cell
counts; and current pain
intensity of at least 4/10
on a numerical rating
scale (NRS)

implanted
pacemaker, heart
defibrillator, brain
stimulator, history of
alcohol abuse and
malignancy

RCT

164

18-75

RCT

46

43-75

Patients with documented
type 1 or type 2 diabetes
>1 year and HbA1C ,
11%, DPN affecting LEs
with at least one positive
sensory symptom,
abnormalities in
amplitude (<6mV),
latency (>6.5ms) or
conduction velocity
(<40m/s) in at least one
motor nerve (tibial or
deep peroneal) and/or in
sural nerve, measurable
sensitive NCV and
evocable potential in the
sural nerve, a MDN Score
>7 points, stable dose of
pain medications or other
diabetic neuropathy
medications during month
leading up to enrollment
Diabetes mellitus type 2,
stable glycemic control,
chronic PDN (at least 6
months) in LEs, at least
two items of the MNSI,
one relevant to general
asthenia and one relevant
to perivascular disease.

Previous tx with
TENS or other
electrotherapy,
implanted
pacemaker,
defibrillator or
neurostimulator,
presence of active
foot ulcer,
amputation of LEs,
concomitant severe
disease limiting
compliance to study
procedures or life
expectancy

54

Treatment with
FREMS (biphasic
sequences, asymmetric
and electrically
balanced pulses with
an active phase of 300V and short
duration proceeded by
a recharging phase of
low voltage and long
duration; variable
pulse frequency 11000Hz.)
Placebo – no electrical
pulses
FREMS and Placebo
administered via
Aptiva device: 4 pairs
of electrodes applied
to LEs

patients with other
non-diabetic
neuropathy,
significant pain of
other etiology or
peripheral vascular
disease

0

Portable TENS unit,
pulse width of 30260ms, intensity 014mA and frequency
2-150 mHz in
constant, burst or
modulated form.

4 weeks, 3 visits/week,
tx group: 30 mins of
low-frequency
microcurrent 30-40
microA via skin
electrodes places on
proximal dorsum pedis
and on top of caput
fibulae on both legs
Placebo group:
Identical to treatment
group but electrodes
not connected to
micro-TENS unit
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Depression Scale, Visual Analogue Scale, Semmes-Weinstein monofilament test. For the
purpose of comparison of studies in this review, focus is geared towards indices measuring pain.
RESULTS
The Bosi et al study was a double-blind, placebo controlled RTC. Assignment of patients
to treatment were randomized and the randomization allocation were concealed from those
enrolling the subjects into the study.1 110 patients were found eligible for the study and 54 were
randomly assigned to receive FREMS and 56 received placebo.1 Assessments of participants
were collected 8 times over a 51 week period. All patients were analyzed in the groups they were
originally randomized into.1 At the conclusion of the study, 32% of subjects were lost and a
“worst-case” analysis was not completes on subjects lost.1 The study showed that both the VAS
score for nighttime pain and daytime pain were significantly reduced in the intention-to-treat
population compared to the placebo group.1 Reduction of >30% or >50% scoring was
significantly higher in the FREMS treatment group in comparison to the placebo group after the
second and third treatment sessions.1 Data in the study was continuous showing an average
change in VAS scoring between treatment and placebo groups and authors reported outcomes
through a change in mean from baseline (baseline values shared in table 2).1 The precision of the
estimate of the treatment effect was P=0.02 which demonstrates statistical significance.1 This
trial confirms safety and efficacy of FREMS in reducing pain in diabetic patients with PDN. 1
Table 2: Baseline characteristic of study participants (values as mean with standard deviation) 1
Baseline Characteristics
Night-time pain, VAS score
Day-time pain, VAS score

Placebo (n=51)
45.2+29.6
40.9+24.0

FREMS (n=50)
41.3+29.7
31.6+26.3
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The Gossrau et al study included 41 patients, 22 in the treatment group and 19 in the
placebo group.2 Characteristics such as body mass index, duration of diabetes and PDN
symptoms and HbA1c of patients were equally distributed through the treatment and placebo
group.2 Randomization allocation was concealed and intention to treat analysis was applied to
the summation of scoring submitted by patients. Scores from the Neuropathic Pain Scale (NPS)
and Pain Disability Index (PDI) were compared before treatment, after treatment and a month
following completion of the treatment.2 There was no significant difference between the
treatment and placebo group after the first two measurements(P>0.18).2 There was also no
significance found in the comparison of the NPS score at the beginning of treatment and after the
follow-up visit a month after treatments ended (P>0.5).2 None of the treatment effects showed
evidence of precision because they all exceeded p-value.2 The relative risk ratio (RRR) was
calculated to be -0.48, the absolute risk ratio (ARR) -0.253, and the numbers needed to treat
(NNT) -4 show a small treatment effect.2 For the PDI score, table 3 displays that the items of the
PDI were not influenced by the micro-TENS treatments.
Table 3: PDI score not influenced by micro-TENS (values as mean with standard deviation)2

PDI

Treatment
Group before
treatment –
T1

Placebo
Group before
treatment –
T1

Treatment
Group after 4
weeks
treatment

Placebo
Group after 4
weeks
treatment

Treatment
group after 1
month
follow-up

Placebo
group after 1
month
follow-up

P value
difference
T1/T2

22.05+ 16.5

21.79+ 15

17.7+ 15.5

18+ 14.6

19.45+ 15.6

18.05+13.5

P > 0.8

P value
difference
T1/T3

P > 0.5

The Moharic and Burger study was an observation study with 46 participants.3 Outcomes
assessed were cold pain and heat pain thresholds and comparisons of outcomes at the beginning
of treatment and 1 month after completion were assessed reporting change in mean from
baseline.3 Cold and heat pain were measured at four sites: the thenar eminence, dorsum of the
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foot, 5cm below the fibular head and the anterior part of the thigh.3 Change in thenar cold and
heat pain were the only two significantly changed thresholds with p-value of 0.0001 as seen in
table 4.3
Table 4: Results from statistical tests of sensory thresholds (thermal thresholds in ºC)3

Thenar
Dorsum of foot
Lateral part of
leg
Anterior part
of thigh

Threshold

Baseline Median

After treatment
Median

One Month after
treatment Median

P value

Cold pain
Hot pain
Cold pain
Hot pain
Cold pain
Hot pain
Cold pain
Hot pain

4.1
47.4
0.0
50.0
2.7
50.0
2.2
47.7

13.2
45.0
0.0
50.0
1.6
49.5
8.1
47.9

15.9
44.5
3.5
50.0
9.9
48.6
12.1
47.4

0.0001*
0.0001*
0.2044
0.7922
0.1202
0.1566
0.1306
0.3944

DISCUSSION
All three studies were unable to exhibit evidence of lasting DPN pain relief using
electroanalgesic treatment. In the Bosi et al study, there was a notable reduction in the VAS
scoring at the conclusion of the study however, the pain reduction was not sustained as many
patients returned to baseline scoring discovered during a 3 month follow up survey.1 In the
Gossrau et al study, the lack of significance found after NPS comparisons between treatment and
placebo group exhibited no difference in reduction pain intensity, pain tolerance and presence of
burning or stabbing pain quality after treatment with the TENS unit. The lack of significant
differences in outcomes showed that general reduction of pain when applying TENS is not a
superior treatment to the placebo treatment.2 Moharic and Burger also concludes the that TENS
did not display significant findings regarding baseline pain thresholds compared to post
treatment thresholds.3

Lee, Electroanalgesic Therapy and Neuropathy, 9

Each study had a limitation in design and implementation of investigation. The Bosi et al.
study had a limitation on their inclusion criteria selecting patients who demonstrated mild
symptomatology excluding diabetic patients with more severe symptoms therefore, possibly
excluding the findings of the study’s application to this population.1 In the Gossrau et al study,
the lower intensity of the currents in a micro-TENS units versus a conventional TENS unit could
be attributed to the low therapeutic efficacy of the treatment.2
CONCLUSION
Two RCTs and one observational study were systematically reviewed for the
effectiveness of electroanalgesic therapy decreasing neuropathic pain in diabetic patients.
Collectively, these studies do not support the efficacy of this modality in the treatment of
diabetic peripheral neuropathic pain. However, the Gossrau et al and Mohari and Burger studies
found lack of significance in comparison groups limitations in the inclusion criteria as well as the
inconsistencies in the modalities of electroanalgesic therapies used across all three studies, there
does remain the question if the ineffectiveness of this treatment is deemed as a conclusive
finding. The safety of electroanalgesic therapy has been demonstrated in all three studies but
evidence of the efficacy of these treatments is lacking. Generally, any evidence of treatment for
diabetic peripheral neuropathic pain is quite limited. There are currently a relatively small
number of studies published on this mode of DPN treatment.
Future study is warranted to evaluate electroanalgesic therapy in a more consistent and
comprehensive evaluation in modality and in the breadth of patient population. In terms of
safety, efficacy and cost it would be of great benefit for future studies to address comparisons of
therapies such as cost-effectiveness studies of the different treatments as to provide more

Lee, Electroanalgesic Therapy and Neuropathy, 10

information to prescribing physicians and to diabetes patients while exploring the best options
for treatment.
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